-
Innovation Ranking
NewInnovation Ranking – OptiNose Inc
OptiNose Inc (OptiNose) is a specialty pharmaceutical company. It offers various products such as fluticasone propionate and sumatriptan nasal powder. Its products are used in the therapeutic areas of nasal inflammatory diseases, nasal congestion and obstruction, chronic rhinosinusitis, facial pain and pressure, drainage and postnasal drip, nasal polyps, autism, narcolepsy and Parkinson’s diseases. OptiNose developed powder delivery device with a disposable drug-containing section and liquid delivery device for medication-carrying airflow into nasal cavity. The company utilizes exhalation delivery system technology...
-
Product Insights
Nasal Polyps (Nasal Polyposis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Nasal Polyps (Nasal Polyposis) - Drugs In Development, 2023’, provides an overview of the Nasal Polyps (Nasal Polyposis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nasal Polyps (Nasal Polyposis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Sinusitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sinusitis - Drugs In Development, 2023’, provides an overview of the Sinusitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Rhinosinusitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Rhinosinusitis - Drugs In Development, 2023’, provides an overview of the Rhinosinusitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rhinosinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Prader-Willi Syndrome (PWS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) - Drugs In Development, 2023’, provides an overview of the Prader-Willi Syndrome (PWS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Autism Spectrum Disorder (ASD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Autism Spectrum Disorder (ASD) - Drugs In Development, 2023’, provides an overview of the Autism Spectrum Disorder (ASD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Autism Spectrum Disorder (ASD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oxytocin in Autism Spectrum Disorder (ASD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Oxytocin in Autism Spectrum Disorder (ASD) Drug Details:Oxytocin (OPN-300) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CYP-001 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CYP-001 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CYP-001 in Graft Versus Host Disease (GVHD) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fluticasone Propionate in Rhinosinusitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fluticasone Propionate in Rhinosinusitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fluticasone Propionate in RhinosinusitisDrug Details:Fluticasone propionate (OPN-375/ Xhance) is a steroid ester derivative,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CFI-402411 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CFI-402411 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CFI-402411 in Solid Tumor Drug Details:CFI-402411 is under development for the treatment of...